Gadobutrol Enhanced MRA of the Supra-aortic Vessels

NCT01344447 | Completed Phase 3 Results DMC

• 2 other identifiers: 146072010-023001-36
• Study Type: interventional
• Target: 479
• Locations: 13 countries
• Sites: 53

Brief Summary

Subjects referred for a routine CTA (computed tomography angiography) or MRA (magnetic resonance angiography) will be invited to participate in the study and subjects will be involved in the study for between 2 and 12 days. Two to three visits to the study doctor will be required. This study will compare the diagnostic results of Gadobutrol enhanced MRA images with MRA images taken without contrast agent using images from a CTA as the standard of reference, which may have been performed up to 60 days prior to enrolment. If a CTA has not been performed in this prior time period, a CTA is required for the study. MRA and CTA images will be collected for an independent review (blinded read).

Conditions

Carotid Stenosis

Keywords

Supra-aortic vascular disease; MRA; CTA; Males and females aged 18 years or older; Stroke; Transient Ischemic Attack (TIA)

Outcome Measures

Primary Outcomes (5)

• Percentage of Assessable Vascular Segments Using Gadobutrol-Enhanced MRA and Unenhanced MRA

  Each vascular segment was visualized using unenhanced MRA and gadobutrol-enhanced MRA, characterized by the on-site investigators, three independent blinded readers (BR) (BR 1, BR 2 and BR 3) and majority readers (the outcome determined by at least two of the blinded readers). A segment was assessable if it was visualized along its entire length and if any region of stenosis, was measured reliably. There were 21 segments of the supra-aortic arteries assessed per participant.

  Images were taken pre-injection and post-injection

• Sensitivity for Detection of Clinically Significant Disease Using Gadobutrol-Enhanced MRA and Unenhanced MRA

  Clinically significant disease was defined as 70 to 99% stenosis of a segment, but not occluded, as assessed by the standard of reference (SoR) (computed tomographic angiography \[CTA\]; blinded readers). This was determined using the North American Symptomatic Carotid Endarterectomy Trial (NASCET) criteria. For each segment, the most severe stenosis/narrowing was identified and considered for the evaluation of clinically significant disease. In case of multiple stenosis in any one segment, the most severe stenosis in the segment was recorded.

  Images were taken pre-injection and post-injection

• Specificity for Exclusion of Clinically Significant Disease Using Gadobutrol-Enhanced MRA and Unenhanced MRA

  Clinically significant disease was defined as 70 to 99% stenosis of a segment, but not occluded, as assessed by the SoR (CTA; blinded readers). This was determined using the NASCET criteria. For each segment, the most severe stenosis/narrowing was identified and considered for the evaluation of clinically significant disease. In case of multiple stenosis in any one segment, the most severe stenosis in the segment was recorded.

  Images were taken pre-injection and post-injection

• Minimum Gadobutrol Performance for Sensitivity: Sensitivity > 50%

  Clinically significant disease was defined as 70 to 99% stenosis of a segment, but not occluded as assessed by the SoR (CTA; blinded readers). For each segment, the most severe stenosis/narrowing was identified and considered for the evaluation of clinically significant disease. Gadobutrol minimum performance criteria was based on a stenosis of 50% calculated from the native vessel diameter.

  Images were taken pre-injection and post-injection

• Minimum Gadobutrol Performance for Specificity: Specificity > 50%

  Clinically significant disease was defined as 70 to 99% stenosis of a segment, but not occluded as assessed by the SoR (CTA; blinded readers). For each segment, the most severe stenosis/narrowing was identified and considered for the evaluation of clinically significant disease. Gadobutrol minimum performance criteria was based on a stenosis of 50% calculated from the native vessel diameter.

  Images were taken pre-injection and post-injection

Secondary Outcomes (15)

• Vessel Diameter (Millimeter [mm]) at the Normal Point and the Narrowest Point in Gadobutrol-Enhanced MRA, Unenhanced MRA and CTA Images

  Images were taken pre-injection and post-injection

• The Percentage of Segments With Artifacts Presence

  Images were taken pre-injection and post-injection

• Types of Artifacts on a Segment Basis by Blinded Reader 1

  Images were taken pre-injection and post-injection

• Types of Artifacts on a Segment Basis by Blinded Reader 2

  Images were taken pre-injection and post-injection

• Types of Artifacts on a Segment Basis by Blinded Reader 3

  Images were taken pre-injection and post-injection

Study Arms (1)

Arm 1

EXPERIMENTAL

Drug: Gadobutrol (Gadovist, BAY86-4875)

Interventions

Gadobutrol (Gadovist, BAY86-4875) DRUG

A single bolus injection of approx. 0.1mmol/kg

Arm 1

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female subjects, aged 18 years and older
• Any of the following:
• Known or suspected supra-aortic arterial disease based on:
• Prior stroke
• Transient ischemic attack (TIA)
• Amaurosis Fugax (transient monocular blindness)
• Referred for evaluation of any supra-aortic vessel (for clinically significant stenosis)
• Follow-up for a stent in a supra-aortic vessel
• Prior imaging study (CTA or ultrasound) showing ≥ 50% stenosis of a supra-aortic vessel segment (within 60 days before consent). The proportion of subjects with positive disease (determined by the investigator, based on CTA or ultrasound) will be monitored during the study, and enrolment may be further restricted to require ≥ 70% stenosis to ensure that overall there are an adequate number of subjects with clinically significant disease for the evaluation of study endpoints.
• Willingness to undergo the routine Contrast Enhanced Magnetic Resonance Angiography \[CE MRA\] examination with gadobutrol
• Willingness and ability to follow directions and complete all study procedures specified in the protocol
• Females of childbearing potential only: Negative pregnancy test on the day of the MRA before the administration of study drug

You may not qualify if:

• Pregnant or nursing (including pumping for storage and feeding)
• Received any other investigational product or participation in any other clinical trial within 30 days before enrollment into this study
• Previous enrollment into this study or into any other Bayer sponsored study using gadobutrol
• Contraindication to the MRA examinations (e.g. inability to hold breath; severe arrhythmias; very low cardiac output, severe claustrophobia, defibrillators or other metallic devices not approved for MRI)
• Contraindication to the use of Gd-containing contrast agents (including subjects with suspicion for or known to have Nephrogenic Systemic Fibrosis \[NSF\])
• History of severe allergic or anaphylactoid reaction to any allergen including drugs and contrast agents
• Received any contrast agent within 72 hours before the study MRA, or scheduled receipt of any contrast agent within 24 hours after the study MRA (Note: This applies also to a CTA potentially scheduled during the course of the study.)
• Estimated glomerular filtration rate (eGFR) value \< 30 ml/min/1.73 m2 derived from a serum creatinine result within 2 weeks before the gadobutrol injection. Any subject on hemodialysis or peritoneal dialysis is excluded from participation. Use the value obtained prior to and closest to the time of the MRA, if there are multiple creatinine values. (Do not use the core lab value if not available prior to the MRA.)
• Acute renal insufficiency of any intensity, either due to hepato-renal syndrome or occurring in the peri-operative liver transplantation period
• Severe cardiovascular disease (e.g. acute myocardial infarction \[\< 14 days\], unstable angina, congestive heart failure New York Heart Association class IV) or known long QT syndrome
• Suspected clinical instability or unpredictability of the clinical course during the study period (e.g. due to previous surgery)
• Scheduled or potentially expected for the period between the CTA and gadobutrol MRA:
• Any procedure that may alter the MRA or CTA interpretation, or
• Any interventional or surgical procedure involving the supra-aortic vessels

Sponsors & Collaborators

• Bayer: lead

Study Sites (56)

Unknown Facility

Tucson, Arizona, 85724, United States

Location

Unknown Facility

Jacksonville, Florida, 32209, United States

Location

Unknown Facility

Savannah, Georgia, 31406, United States

Location

Unknown Facility

Louisville, Kentucky, 40202, United States

Location

Unknown Facility

Baltimore, Maryland, 21201, United States

Location

Unknown Facility

Boston, Massachusetts, 02114, United States

Location

Unknown Facility

Ann Arbor, Michigan, 48109-0330, United States

Location

Unknown Facility

Jackson, Mississippi, 39216, United States

Location

Unknown Facility

Rochester, New York, 14642, United States

Location

Unknown Facility

The Bronx, New York, 10467, United States

Location

Unknown Facility

Philadelphia, Pennsylvania, 19104, United States

Location

Unknown Facility

Providence, Rhode Island, 02903, United States

Location

Unknown Facility

Memphis, Tennessee, 38104, United States

Location

Unknown Facility

Seattle, Washington, 98195, United States

Location

Unknown Facility

Madison, Wisconsin, 53792, United States

Location

Unknown Facility

Adrogué, Buenos Aires, B1846DWA, Argentina

Location

Unknown Facility

Buenos Aires, Ciudad Auton. de Buenos Aires, C1115AAB, Argentina

Location

Unknown Facility

Buenos Aires, Ciudad Auton. de Buenos Aires, C1425BEE, Argentina

Location

Unknown Facility

New Lambton Heights, New South Wales, 2305, Australia

Location

Unknown Facility

Clayton, Victoria, 3168, Australia

Location

Unknown Facility

Parkville, Victoria, 3052, Australia

Location

Unknown Facility

Innsbruck, Tyrol, 6020, Austria

Location

Unknown Facility

Vienna, 1090, Austria

Location

Unknown Facility

Shanghai, 200032, China

Location

Unknown Facility

Shanghai, 200433, China

Location

Unknown Facility

Brno, 62500, Czechia

Location

Unknown Facility

Brest, 29609, France

Location

Unknown Facility

Bron, 69677, France

Location

Unknown Facility

Marseille, 13385, France

Location

Unknown Facility

Paris, 75877, France

Location

Unknown Facility

Paris, 75908, France

Location

Unknown Facility

Karlsruhe, Baden-Wurttemberg, 76133, Germany

Location

Unknown Facility

Augsburg, Bavaria, 865156, Germany

Location

Unknown Facility

Erlangen, Bavaria, 91054, Germany

Location

Unknown Facility

Münster, North Rhine-Westphalia, 48145, Germany

Location

Unknown Facility

Jena, Thuringia, 07740, Germany

Location

Unknown Facility

Aosta, Aosta Valley, 11100, Italy

Location

Unknown Facility

Ferrara, Emilia-Romagna, 44023, Italy

Location

Unknown Facility

Rome, Lazio, 00168, Italy

Location

Unknown Facility

Catania, Sicily, 95123, Italy

Location

Unknown Facility

Massa-Carrara, Tuscany, 54100, Italy

Location

Unknown Facility

Venezia, Veneto, 30174, Italy

Location

Unknown Facility

Bydgoszcz, 85-094, Poland

Location

Unknown Facility

Lodz, 90-153, Poland

Location

Unknown Facility

Warsaw, 02-097, Poland

Location

Unknown Facility

Wroclaw, 50-556, Poland

Location

Unknown Facility

Donggu, Gwangju Gwang''yeogsi, 61469, South Korea

Location

Unknown Facility

Seoul, 03722, South Korea

Location

Unknown Facility

Seoul, 05505, South Korea

Location

Unknown Facility

Seoul, 06351, South Korea

Location

Unknown Facility

Linköping, 581 85, Sweden

Location

Unknown Facility

Uppsala, 751 85, Sweden

Location

Unknown Facility

Sankt Gallen, Canton of St. Gallen, 9007, Switzerland

Location

Unknown Facility

Antalya, 07059, Turkey (Türkiye)

Location

Unknown Facility

Erzurum, 25240, Turkey (Türkiye)

Location

Unknown Facility

Istanbul, 34093, Turkey (Türkiye)

Location

Related Links

• Click here to find information about studies related to Bayer Healthcare products conducted in Europe

MeSH Terms

Conditions

Carotid Stenosis; Stroke; Ischemic Attack, Transient

Interventions

gadobutrol

Condition Hierarchy (Ancestors)

Carotid Artery Diseases; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Arterial Occlusive Diseases; Vascular Diseases; Cardiovascular Diseases; Brain Ischemia

Results Point of Contact

• Title: Therapeutic Area Head
• Organization: BAYER

clinical-trials-contact@bayerhealthcare.com

Study Officials

• Bayer Study Director

  Bayer

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: NA
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 5, 2011
• First Posted: April 29, 2011
• Study Start: May 12, 2011
• Primary Completion: May 28, 2014
• Study Completion: May 28, 2014
• Last Updated: January 4, 2019
• Results First Posted: August 26, 2015

Record last verified: 2018-12

Locations

FR (5); IT (6); AR (3); CZ (1); KR (4); CN (2); SE (2); CH (1); TU (3); AU (2); PL (4); DE (5); US (15)